Background. Despite effective local therapy with surgery and radiotherapy (RT), *50 % of patients with high-grade soft tissue sarcoma (STS) will relapse and die of disease. Since experimental data suggest a significant synergistic effect when antiangiogenic targeted therapies such as sorafenib are combined with RT, we chose to evaluate preoperative combined modality sorafenib and conformal RT in a phase I/II trial among patients with extremity STS amenable to treatment with curative intent. Methods. For the phase I trial, eight patients with intermediate-or high-grade STS [5 cm in maximal dimension or low-grade STS [8 cm in maximal dimension received concomitant sorafenib (dose escalation cohort 1:200 twice daily, cohort 2:200/400 daily) and preoperative RT (50 Gy in 25 fractions). Sorafenib was continued during the entire period of RT as tolerated. Surgical resection was completed 4-6 weeks following completion of neoadjuvant sorafenib/ RT. Three sorafenib dose levels were planned. Primary endpoints of the phase I trial were maximal tolerated dose and dose-limiting toxicity (DLT). Results. Eight patients were enrolled in the phase I (five females, median age 44 years, two high-grade pleomorphic, two myxoid/round cell liposarcoma, four other). Median tumor size was 16 cm (range 8-29), and all tumors were located in the lower extremity. Two of five patients treated at dose level 2 developed DLT consisting of grade 3 rash not tolerating drug reintroduction. Other grade 3 side effects included anemia, perirectal abscess, and supraventricular tachycardia. Radiation toxicity (grade 1 or 2 dermatitis; N = 8) and post-surgical complications (three grade 3 wound complications) were comparable to historical controls and other series of preoperative RT monotherapy. Complete pathologic reponse (C95 % tumor necrosis) was observed in three patients (38 %). Conclusion. Neoadjuvant sorafenib in combination with RT is tolerable and appears to demonstrate activity in locally advanced extremity STS. Further study to determine efficacy at dose level 1 is warranted. (ClinicalTrials.gov identifier NCT00805727).
among cases of extremity soft tissue sarcoma (STS), 1 patients with high-grade tumors have a risk of distant recurrence and death approaching 50 % within 5 years of diagnosis. Therefore, despite the recent US FDA approval of pazopanib for metastatic STS, novel combined modality approaches are needed.
Angiogenesis is a fundamental component of tumor development and acquisition of the metastatic phenotype. 2, 3 Overexpression of vascular endothelial growth factor (VEGF) and its receptors has been observed as a near universal neoplastic phenomenon, and STSs have been shown to overexpress angiogenic factors in both tumor tissue and serum. [4] [5] [6] In addition, early-stage clinical trials suggest that the combination of RT and antiangiogenic agents may exhibit a synergistic effect. 7, 8 These data support the hypothesis that neoadjuvant/adjuvant therapy with tyrosine kinase inhibitors (TKIs) in combination with RT may demonstrate enhanced activity for patients with STS.
Sorafenib is a multikinase inhibitor with antiproliferative and antiangiogenic effects. The safety and clinical activity of sorafenib has been examined in phase I studies conducted in patients with solid tumors. 9, 10 Phase III clinical trials have established the efficacy of sorafenib for patients with renal cell and hepatocellular carcinoma. 11, 12 Given its favorable toxicity profile, its potential synergistic effect with RT, and evidence for activity in the metastatic setting, we sought to test the hypothesis that preoperative combined modality sorafenib and conformal RT would be safe for patients with locally advanced STS of the extremity.
PATIENTS AND METHODS

Patient Selection
Eligible patients were aged C18 years, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with pathologically confirmed STS of the extremity, either intermediate-or high-grade histology C5 cm in maximal dimension, or low-grade histology C8 cm in maximal dimension, with no evidence of metastatic disease. Additional inclusion and exclusion criteria are provided in the electronic supplementary material as supplemental Table 1 . Both the UC Davis Scientific Review Committee and the Institutional Review Board reviewed and approved the study protocol and informed consent form prior to any patient being registered on this study. We obtained written informed consent from all patients prior to study entry.
Study Design
The primary objective of the phase I trial was to evaluate safety and toxicity, and the primary endpoint was maximal tolerated dose (MTD). A traditional dose-escalation design was used to determine MTD (ClinicalTrials.gov identifier NCT00805727). For the determination of sorafenib-related adverse events (AEs), we based our evaluation on the time between initiation of concurrent sorafenib/RT and the date of surgery.
The MTD was defined as one dose level below that which produced dose-limiting toxicity (DLT) in 33 % of patients. The study was designed to evaluate three dose levels, based on a starting dose of 200 mg twice daily, since the combination of sorafenib/RT had not been previously evaluated in a prospective clinical trial. Since 400 mg twice daily is the well-established MTD for sorafenib monotherapy, the study was not designed to escalate above this level. Dose-level escalation was based on DLTs observed from the start of treatment until the date of definitive operation, but we also monitored DLTs in the postoperative period. A formal stopping rule, evaluating post-surgical AEs, was prespecified for the phase II trial. We elected not to include a confirmation cohort for dose level 1 since we were assessing the novel combination of two previously FDA-approved drugs/modalities with welldescribed safety data.
13,14
Study Procedures
Sorafenib was initiated concomitant with RT on day 1 of study treatment. RT consisted of a total dose of 50 Gy delivered in 25 fractions of 200 cGy. RT treatment planning was based on a radial margin of *2 cm and a longitudinal margin of *3 cm beyond the gross disease.
Surgical resection occurred day 50-90 of the study to allow for the acute toxicities of neoadjuvant therapy to resolve. Routine perioperative care was provided, but careful documentation of wound complications was an integral part of this clinical trial. Wound complications were defined as described by O'Sullivan et al. 1 
Toxicity Assessment
Physical examinations, blood pressure (BP) monitoring, and routine laboratory studies were performed at study initiation. Physical examinations and BP monitoring were conducted weekly during concomitant sorafenib/RT treatments and then biweekly prior to surgical resection. AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Definition of Dose-Limiting Toxicity
Per protocol, dose-level escalation was based on DLTs observed from the start of treatment until the date of surgery. DLT was defined as grade 4 anemia, grade 4 neutropenia lasting [7 days, grade 3-4 thrombocytopenia with clinically significant bleeding, or grade 4 thrombocytopenia lasting [5 days, and grade 3-4 non-hematologic toxicity except for nausea/vomiting that responded to antiemetic therapy, grade 3 neutropenic fever lasting B5 days, grade 3 encephalopathy lasting B2 days, grade 3-4 hypokalemia, hypophosphatemia, or hypomagnesemia unless hospitalization was required, grade 3 diarrhea controlled with medication within 2 days, and grade 3 hypertension that was not adequately controlled with medication (BP \150/100). We also prospectively articulated a treatment stop rule for the phase II portion of the trial after ten patients had completed concurrent sorafenib, RT, and surgical resection to assess for a possible increased rate of overall AEs.
Radiologic and Pathologic Response
Radiologic response was evaluated by contrast-enhanced magnetic resonance imaging using the Response Evaluation Criteria in Solid Tumors (RECIST). Post-treatment imaging was obtained 1-2 weeks prior to surgical resection.
All pathology slides were subjected to central review by a subspecialty sarcoma pathologist (DB). Specimens were examined for determination of percentage tumor necrosis as defined previously. 15, 16 Complete or near-complete pathologic response (path CR) was defined as C95 % tumor necrosis. 16, 17 Serum Biomarkers Exploratory molecular correlative analyses were conducted on serial plasma specimens. Blood samples were collected into a tube containing potassium EDTA and were centrifuged at 4°C within 10-15 min. Multiplex analysis using Luminex technology was used to determine plasma levels of growth and angiogenic factors. Samples were measured in duplicate.
The rationale for the assessment of biomarkers was based on the pleotropic effects of sorafenib which affects tumor cell proliferation through the Raf/MEK/ERK signaling pathway, and angiogenesis through the VEGFR pathway. [18] [19] [20] In addition, hypoxia has profound effects on radioresistance, mediated in part through the hypoxiainducible factor 1-a (HIF-1a) transcription factor. 5, 6, 21 Therefore, we evaluated changes in the serum expression of these proteins as predictors of response and/or resistance to treatment.
Statistical Considerations
Summary statistics were reported as mean ± standard error with median/range where appropriate. We analyzed serum biomarker levels using a repeated measures analysis of variance (ANOVA) to compare repeated measurements in individual biomarkers over time between responders (path CR) and non-responders. We first tested the interaction terms between the timepoints and the groups. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). Significance was set at p \ 0.05.
RESULTS
Patient and Tumor Characteristics
Between July 2009 and November 2011, eight patients underwent treatment. The baseline patient and tumor characteristics are depicted in Table 1 . Two patients had low-grade tumors, including an 8 cm myxoid liposarcoma involving the sciatic nerve and a 29 cm well-differentiated liposarcoma with concern on preoperative imaging for a dedifferentiated component. Two patients (25 %) underwent R1 resections, including one patient with a gross complete resection but a microscopic positive margin along the sciatic nerve, and one patient with well-differentiated liposarcoma with gross complete resection with tumor capsule intact but a \1 mm microscopic margin.
Toxicity
Toxicity from combined modality therapy is depicted in Table 2 . Two of five patients treated at sorafenib dose level 2 experienced DLT consisting of grade 3 macular-papular rash not tolerating drug reintroduction. Other grade 3 side effects included anemia, perirectal abscess, and supraventricular tachycardia (SVT). Patient 6 developed grade 3 anemia (hemoglobin 6.9 g/dL) with concomitant SVT. This event was classified as possibly related to protocol therapy, but not considered a DLT given the protocol specifications regarding hematologic toxicities. Patient 8 developed a perirectal abscess after completion of neoadjuvant treatment but prior to surgical resection. This was classified as not related to protocol therapy. One patient (12 %) developed hand-foot syndrome/palmar-plantar erythrodysesthesia.
Radiation-related toxicity and post-surgical wound complications are depicted in Table 2 . Radiation toxicity (grade 1 or 2 dermatitis; N = 8) and post-surgical complications (38 % grade 3 wound complications) were comparable to rates anticipated with preoperative RT monotherapy.
Radiographic and Pathologic Response to Treatment
Seven patients experienced stable disease by RECIST criteria, and one patient had a partial response. Three study patients (38 %) demonstrated path CR (Table 2) , including one patient (1/3) at dose level 1 and two patients at dose level 2 (2/5). The association of tumor size, tumor histology, and tumor necrosis is depicted in Table 3 .
Serum Biomarkers
The results of serial biochemical testing for angiogenic and growth factors are depicted in Fig. 1a-d . Overall, there were no significant differences in the serum levels of these biomarkers among pathologic responders and nonresponders at any of the timepoints. VEGF (Fig. 1c) , in particular, showed no appreciable differences among responders and non-responders at any timepoint. In contrast, there was a trend among non-responders to have rising levels of epidermal growth factor and plateletderived growth factor-AA at day 60 as well as persistently elevated levels of basic fibroblast growth factor at each timepoint.
Oncologic Outcome
With a median follow-up of 30 months, 3-year overall survival, local recurrence-free survival, and distant recurrence-free survival were 75, 100, and 42 %, respectively. There were four distant recurrences. These occurred at 3, 3, 6, and 31 months, respectively. Two of these patients [clear 
DISCUSSION
Although limb-sparing surgery combined with RT is highly effective in the local management of extremity STS, distant disease control remains a significant problem for these patients, particularly those with high-grade histologic subtypes. 22 Because of the high-risk nature of American Joint Committee on Cancer (AJCC) stage 3 STS, adjuvant and neoadjuvant chemotherapy has frequently been advocated for patients with locally advanced STS. However, studies utilizing traditional cytotoxic chemotherapeutic agents, either alone or in combination with RT, have been equivocal, and prospective studies that have demonstrated improved outcomes following adjuvant chemotherapy are mitigated by other studies demonstrating no benefit or loss of benefit with longer follow-up. [23] [24] [25] [26] [27] A recent updated meta-analysis of the role of perioperative chemotherapy in the management of locally advanced, but non-metastatic, STS observed a modest but statistically significant benefit in favor of adriamycin/ifosfamide-based chemotherapy. 28 However, there is significant concern about the potential toxicities of cytotoxic chemotherapy in the management of localized STS, particularly when the oncologic benefits appear to be modest. Therefore, the evaluation of novel therapeutic agents for the treatment of STS appears warranted. One of the benefits of neoadjuvant therapy is the ability to monitor disease response, including pathologic response, as a surrogate marker of oncologic outcome.
Sorafenib is pleotropic TKI with antiangiogenic and antiproliferative properties. 18 It is FDA-approved in the management of metastatic renal cell carcinoma and hepatocellular carcinoma. Phase II studies have demonstrated activity and clinical benefit for patients with metastatic STS. 29, 30 Maki et al., 29 for example, observed a clinical benefit rate (complete response ? partial response ? stable disease) of 56 % at 3 months among 122 patients with recurrent or metastatic STS. Patients with angiosarcoma and leiomyosarcoma experienced the most favorable responses. Similarly, von Mehren et al. 30 evaluated sorafenib in a multi-institutional phase II study of patients with metastatic STS. Although there were no patients with radiographic response, six patients (75 %) with vascular sarcomas experienced clinical benefit for C6 months.
Furthermore, preclinical data suggest a significant synergistic effect when antiangiogenic-targeted therapies are combined with RT. 19, 31 Antiangiogenic therapies appear to 'normalize' the tumor vasculature, thereby rendering it less hypoxic and more sensitive to RT. 2, 3, 32 This potential radiosensitization is significant in STS since complete and near-complete pathologic response have been associated with improved oncologic outcomes in STS patients treated with neoadjuvant therapy. 17, 33, 34 Furthermore, a key randomized clinical trial evaluating preoperative versus postoperative RT for extremity STS patients undergoing resection with curative intent demonstrated that overall survival was statistically improved in the patients who received preoperative RT (85 vs. 75 % at 3 years; p = 0.048).
1 However, it is important to note that the survival data from this trial were a secondary endpoint. Given that no differences were observed in progressionfree survival or regional/distant recurrences between the preoperative and postoperative RT cohorts, these survival data should be viewed with caution. Nevertheless, it is reasonable to hypothesize that neoadjuvant RT in combination with novel systemic agents, such as sorafenib, may improve both local and distant disease-control in patients with STS, potentially through immune-mediated effects. 22, 35 The primary objective of this phase I trial was to evaluate safety and toxicity and thereby determine the MTD. Our data demonstrate that sorafenib can be administered safely in the neoadjuvant setting in combination with 29, 30 while the incidence of hand-foot syndrome was low (12 %) . No unanticipated side effects were observed, and the rates of RT and post-surgical morbidities were consistent with those observed in other studies of these modalities. 1, 33 Although this phase I study was not designed to evaluate therapeutic response, we did observe a 38 % rate of path CR, including one patient (1/3) at dose level 1 and two patients at dose level 2 (2/5). Conversely, we observed four distant recurrences and two disease-related deaths during follow-up of our cohort. These oncologic outcomes do not appear superior to historical controls. 33, 36 This discrepancy between pathologic response and oncologic outcome may be related to the relatively short period of exposure to sorafenib as systemic therapy in our study. Other early-phase clinical trials of novel neoadjuvant therapies have resumed therapy for responding patients in the postoperative period. This approach may translate into superior distant disease control and long-term oncologic outcome. Another potential limitation of our study is the lack of stratification based on histology. As has been observed in the metastatic setting, there are differences in STS response rates to sorafenib based on histologic type, and differences in radiosensitivity among STS histologies have also been demonstrated. 33, [37] [38] [39] We intend to address this important issue in the phase II setting by employing a histology-based clinical trial design which includes both a myxoid and nonmyxoid histology arm. 
CONCLUSIONS
Among patients with locally advanced extremity STS, neoadjuvant sorafenib in combination with conformal RT is tolerable and appears to show activity. The results of this phase I trial indicate that dose level 1 (200 mg twice daily) is the appropriate MTD. Further study to determine efficacy at this level appears warranted.
